Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting

Back to Jobs

SAN DIEGO , Feb. 16, 2022 (GLOBE NEWSWIRE) —  Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upcoming presentations on the OTO-413 hearing loss program at the 49 th Annual Scientific and

Apply Now